Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction

• Verfasst von: Opelz, Gerhard [VerfasserIn]
• Verfasst von: Morath, Christian [VerfasserIn]
• Verfasst von: Süsal, Caner [VerfasserIn]
• Verfasst von: Tran, Thuong Hien [VerfasserIn]
• Verfasst von: Zeier, Martin [VerfasserIn]
• Verfasst von: Döhler, Bernd [VerfasserIn]
• Titel: Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction
• Titelzusatz: results from 101 centers
• Verf.angabe: Gerhard Opelz, Christian Morath, Caner Süsal, Thuong Hien Tran, Martin Zeier, and Bernd Döhler
• Jahr: 2015
• Umfang: 5 S.
• Fussnoten: Gesehen am 24.06.2020
• Titel Quelle: Enthalten in: Transplantation
• Ort Quelle: Hagerstown, Md. : Lippincott Williams & Wilkins, 1963
• Jahr Quelle: 2015
• Band/Heft Quelle: 99(2015), 2, Seite 400-404
• ISSN Quelle: 1534-6080
• DOI: doi:10.1097/TP.0000000000000312
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1702015068

Abstract

Background - Reports from experienced centers suggest that recipients of an ABO-incompatible living-donor kidney transplant after reduction of ABO antibodies experience no penalty in graft and patient survival versus ABO-compatible transplants, but confirmation that these results can be widely replicated is lacking. - Methods - Living-donor kidney transplants from ABO-incompatible donors after ABO antibody reduction registered with the Collaborative Transplant Study during 2005 to 2012 were analyzed and compared with (i) a matched group of ABO-compatible transplant recipients and (ii) all ABO-compatible transplants from centers that performed at least five ABO-incompatible grafts during the study period. - Results - One thousand four hundred twenty living-donor ABO-incompatible kidney transplants were analyzed. Three-year death-censored graft survival was virtually identical for ABO-incompatible transplants versus matched and center controls (P = 0.92 and P = 0.60, respectively). Patient survival rates were also similar (P = 0.15 and P = 0.11, respectively). Early patient survival was lower in ABO-incompatible grafts (P = 0.006 vs. matched controls; P = 0.001 vs. center controls) because of a higher rate of early infectious death (P = 0.037 and P < 0.001, respectively). Death-censored graft and patient survival were not significantly affected by induction therapy and anti-CD20 treatment. ABO antibody reduction by column adsorption was associated with similar death-censored graft survival to plasmapheresis. - Conclusion - In this analysis of prospectively collected data from a large series of ABO-incompatible living-donor kidney transplants performed at 101 centers, death-censored graft and patient survival rates were similar to those achieved in ABO-compatible control groups over the same period.